Antimicrobial effect of Morita-Baylis-Hillman adducts against oral pathogens and cellular viability in human leukocytes / Efeito antimicrobiano de adutos de Morita-Baylis-Hillman contra patógenos orais e viabilidade celular em leucócitos de humanos

The aim of this work was to evaluate Morita-Baylis-Hillman adduct (MBHA) antimicrobial effect against oral pathogens and related cell viability in human leukocytes. Minimum inhibitory concentration (MIC) was determined using microdilution method. Cell viability was assessed in human peripheral blood mononuclear cells (PBMCs) using the resazurin assay. For S. aureus (ATCC 15656) and S. mutans (UA 159) MIC values of 2,000 μg/mL were reported for the A 1 Morita-Baylis-Hillman adducts. The MICs of the A 2 and A 3 adducts were not found for the bacterial strains. MIC values for the A 1 adduct was 125 μg/mL, A 2 1,000 μg/mL and A 3 to 15.6μg/mL against the C. albicans strain (ATCC 11006). PBMCs showed cell viability greater than 50 % when in contact with concentrations 10x higher than MIC of MBHA. It is concluded that MBHA A 1 , A 2 and A 3 present potential antimicrobial effects against C. albicans without presenting substantial cytotoxic effects in human cells, highlighting adduct A 3 for future therapeutic applications.